We are pleased to advise that deep linking capability, enabling users to directly download individual mobile toolkits, has now been released on the RDS mobile app. When you install the update, you will see that each toolkit has a small QR code icon the header area beside the search icon – see screenshot below. Clicking on this icon will open up a window with a full-size QR code and the alternative of a short URL for sharing with users. Instructions are provided.
You may need to actively install the update to install RDS app version 4.7.1 to see this improvement. Installing this update is also strongly recommended to get the full benefits of the new contingency arrangements – specifically, that if the RDS website should fail, you will still be able to download new mobile app toolkits.
To check your current RDS version, click on the three dots bottom right of the RDS app screen. This takes you to a “More” page where you will see the version number. To install latest updates:
On iPhones – go to the Apple store, click on your profile icon top right, scroll down to see the apps waiting to be updated and update the RDS app.
On Android phones – these can vary, but try going to the Google Play store, click on your profile icon top right, click on “Manage apps and device”, select and update the RDS app.
Please get in touch with ann.wales3@nhs.scot with any questions.
IMPORTANT! In June 2024 the MHRA issued new safety measures for the use of topiramate during pregnancy due to risks to the unborn child. Topiramate should not be used in women of childbearing potential unless the conditions of the Pregnancy Prevention Programme are fulfilled. This aims to ensure that all women of childbearing potential: are using highly effective contraception, have a pregnancy test to exclude pregnancy before starting topiramate, and are aware of the risks from use of topiramate. Further information is available: Topiramate (Topamax): introduction of new safety measures, including a Pregnancy Prevention Programme. The guideline is under review to take account of this advice.
Given that migraine without aura often improves during pregnancy women should aim to stop migraine prophylactic treatments before pregnancy.
Migraine with aura often continues unchanged.
Before commencing treatment, potential harmful effects of therapies need to be discussed with women who are, or may become, pregnant.
Due to its safety profile, paracetamol is first choice for the short-term relief of mild-to-moderate headache during any trimester of pregnancy.
Consider sumatriptan in all stages of pregnancy. The risk associated with use should be discussed before commencing treatment.
Aspirin, in doses for migraine, is not an analgesic of choice during pregnancy and should not be used in the third trimester of pregnancy.
Therapies to avoid during pregnancy or breastfeeding:
Before commencing treatment with topiramate women should be informed of:
Although initiation of valproate is not recommended for those under the age of 55, for those who are on it and who fulfil MHRA requirements, inform the patient of the risks to children exposed to valproate in utero and the need to use effective contraception - see www.fsrh.org/standards-and-guidance/fsrh-guidelines-and-statements.
Check the Medicines and Healthcare products Regulatory Agency (MHRA) website for current advice.
Pharmacological management of migraine (SIGN)
